Concepedia

Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis

Jeffrey A. Cohen, Anna N. Belova, Krzysztof Selmaj, Christian Wolf, Maria Pia Sormani, Janine Oberyé, Evelyn van den Tweel, R. J. Mulder, N.P. Koper, Gerrit Voortman,

JAMA Neurology · 2015 · 73 citations · 19 references

DOI

Abstract

clinicaltrials.gov Identifier: NCT01489254.

References

19

Rating neurologic impairment in multiple sclerosis

John F. Kurtzke · Neurology · 1983 · 14.7K citations

Diagnostic criteria for multiple sclerosis: 2010 Revisions to the McDonald criteria

Chris H. Polman, Stephen C. Reingold, Brenda Banwell et al. · Annals of Neurology · 2011 · 9.7K citations · Full text

, , +15

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

K. P. Johnson, Benjamin Brooks, J. A. Cohen et al. · Neurology · 1995 · 1.9K citations

Placebo-Controlled Phase 3 Study of Oral BG-12 or Glatiramer in Multiple Sclerosis

Robert J. Fox, David H. Miller, J. Theodore Phillips et al. · New England Journal of Medicine · 2012 · 1.3K citations · Full text

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging--measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group.

Giancarlo Comi, Massimo Filippi, Jerry S. Wolinsky · PubMed · 2001 · 691 citations

, , +15